Effect of device inhalational resistance on the three-dimensional configuration of the upper airway

Journal of Pharmaceutical Sciences

Volumn 94, Issue 7, 2005, Pages 1418-1426

  Ehtezazi, Touraj ^a,b   Horsfield, Mark A ^a   Barry, Peter W ^a   Goodenough, Paul ^a   O'Callaghan, Christopher ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Aerosol therapy; Asthma; Device airflow resistance; Dry powder inhaler; Upper airway shape

Indexed keywords

ADULT; AIRWAY RESISTANCE; ARTICLE; ASTHMA; DEVICE; DRY POWDER; HUMAN; HUMAN EXPERIMENT; IMAGE PROCESSING; INHALER; LARYNX; LUNG DEPOSIT; MALE; MOUTH CAVITY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX; SHEAR STRESS; TRACHEA; UPPER RESPIRATORY TRACT; VOLUNTEER;

EID: 23844451700     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20356     Document Type: Article

References (31)

1. deBoer AH, Gjaltema D, Hagedoorn P. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 138:45-56.
2. Finlay WH. 2001. An introduction: The mechanics of inhaled pharmaceutical aerosol. London: Academic Press.
3. de Koning JP, van der Mark TW, Coenegracht PM, Tromp TF, Frijlink HW. 2002. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm 234:257-266.
4. Li WI, Perzl M, Heyder J, Langer R, Brain JD, Englemeier KH, Niven RW, Edwards DA. 1996. Aerodynamics and aerosol particle deaggregation phenomena in model oral-pharyngeal cavities. J Aerosol Med 27:1269-1286.
5. Li WI, Edwards DA. 1997. Aerosol particle transport and deaggregation phenomena in the mouth and throat. Adv Drug Deliv Rev 26:41-49.
6. DeHaan WH, Finlay WH. 2001. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J Aerosol Med 14:361-367.
7. Ehtezazi T, Horsfield MA, Barry PW, O'Callaghan C. 2004. Dynamic change of the upper airway during inhalation via aerosol delivery devices. J Aerosol Med 17:325-334.
8. McRobbie DW, Pritchard S, Quest RA. 2003. Studies of the human oropharyngeal airspaces using magnetic resonance imaging. I. Validation of a three-dimensional MRI method for producing ex vivo virtual and physical casts of the oropharyngeal airways during inspiration. J Aerosol Med 16:401-415.
9. Cain WT, Cable G, Oppenheimer JJ. 2001. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy Clin Immunol 108:918-920.
10. Schwab RJ, Gupta KB, Gefter WB, Metzger LJ, Hoffman EA, Pack AI. 1995. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 152:1673-1689.
11. Schwab RJ, Pack AI, Gupta KB, Metzger LJ, Oh E, Getsy JE, Hoffman EA, Gefter WB. 1996. Upper airway and soft tissue structural changes induced by CPAP in normal subjects. Am J Respir Crit Care Med 154:1106-1116.
12. Hajnal JV, Saeed N, Soar EJ, Oatridge A, Young IR, Bydder GM. 1995. A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J Comput Assist Tomogr 19: 289-296.
13. deBoer AH, Winter HMI, Lerk CF. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int J Pharm 130:231-244.
14. British Pharmacopoeia. 2004. Preparations for inhalation. Powders for inhalation. Tests. Uniformity of delivered dose. Volume III, pp 2117-2121.
15. European Pharmacopoiea. 2002. Preparations for inhalation. 4th edition, pp 552-556.
16. USP 27 NF22. 2004. Aerosols, metered dose inhalers, and dry powder inhalers, pp 2253-2269.
17. Penson RT, Joel SP, Roberts M, Gloyne A, Beckwith S, Slevin ML. 2002. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Br J Clin Pharmacol 53:347-354.
18. Agu RU, Ugwoke MI, Armand M, Ringet R, Verbeke N. 2001. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2:198-209.
19. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, Smithson WA, Burch P, Gornet M, Rahman E. 1999. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 5:2316-2323.
20. Borgstrom L, Bengtsson T, Derom E, Pauwels R. 2000. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 193:227-230.
21. Svartengren K, Lindestad P, Svartengren M, Philipson K, Bylin G, Camner P. 1995. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 152:32-37.
22. Svartengren K, Anderson M, Svartengren M, Philipson K, Camner P. 1996. Oropharyngeal deposition of 3.5 microns particles inhaled through an elongated mouthpiece. Eur Respir J 9:1556-1559.
23. De Boeck K, Alifier M, Warmer G. 1999. Is the correct use of a dry powder inhaler (Turbohaler) age dependent? J Allergy Clin Immunol 103:763-767.
24. Borgstrom L, Newman SP. 1993. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler. Int J Pharm 97:47-53.
25. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. 2001. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 95:720-727.
26. Vidgren M, Paronen P, Vidgren P, Vainio P, Nuutinen J. 1990. In vivo evaluation of the new multiple dose powder inhaler and the Rotahaler using the gamma scintigraphy. Acta Pharm Nord 2:3-10.
27. Newman SP, Busse WW. 2002. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 96:293-304.
28. Olsson B, Borgstrom L, Asking L, Bondesson E. 1996. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press, pp 273-281.
29. Bosquillon C, Lombry C, Preat V, Vanbever R. 2001. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 70:329-339.
30. Finlay WH, DeHaan W, Grgic B, Heenan A, Matida EA, Hoskinson M, Pollard A, Lange CF. 2002. Fluid mechanics and particle deposition in the oropharynx: The factors that really matter. Respiratory Drug Delivery VIII. Buffalo Grove: Interpharm Press, pp 171-177.
31. Larhrib H, Martin GP, Marriott C, Prime D. 2003. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 257:283-296.